Komori
Y

YAMASHITA HEALTH CARE HOLDINGS,INC.

9265Trading & Wholesale
3,730JPY+9.9%
★ Watch (sign-up required)
Price history
¥3,730Latest+103.2%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

In summary, based on the description in Part I, the Group operates as a holding company, providing management oversight and related services to its subsidiaries. With 8 consolidated subsidiaries, its core business is the sale of medical devices. This business comprises 5 fields: general equipment, general consumables, minimally invasive treatment, specialized products, and information and services, through which it sells medical devices and provides various services to medical institutions and other customers. In medical device manufacturing and sales, the Group manufactures and sells orthopedic implants, including its proprietary intramedullary fixation system Alexanail, and develops and sells ultrasound-based medical devices. The medical mall business leases premises to and manages healthcare-related facilities such as medical clinics, dispensing pharmacies, and day-service facilities. The medical device sales business comprises the same 5 fields and includes activities in minimally invasive treatment, such as endoscopy, surgical, and cardiovascular products, as well as information and services, including MEDiPlaza. Sales to external customers are concentrated mainly in the Japanese market.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Key numbersShowing 8 of 17
PER
13.97How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
0.97How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
6.9%Earning power. A figure above 10% is generally considered good.
Equity ratio
34.6%The proportion of assets funded by money that does not have to be repaid.
Operating margin
1.1%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
3.3%The average annual growth in sales over the past three years.
Forward P/E
16.37Forward P/E based on estimated earnings for the next fiscal year.
PSR
0.14The number of times sales are valued. Used to assess companies that are not profitable.
What to watch next
Plan to establish the new Shin-Tosu TMS Center (total investment: ¥2,173 million; construction start: March 2024; scheduled completion: March 2027)
Around March 2027 (scheduled completion)Impact HighLikelihood Medium
Improved operating efficiency as the introduction of logistics automation, including automated warehouses, transport robots and WMS, progresses
Impact MediumLikelihood Medium
An increase in facilities under SPD contracts, market adoption of web-based materials management systems such as MeRCare-y, and monetization of procurement management consulting
From 2026 onward, in stagesImpact MediumLikelihood Medium
Progress in the clinical evaluation of the Breast Scan ultrasound diagnostic imaging system, providing clues as to when it may become a commercial product
Impact HighLikelihood Low
What to watch next
Loading
Who owns itTop holders total 68.4%
Listed holders 68.4%Everyone else 31.6%
Yamashita Naoto (山下 尚登)24.44%
Yamashita Healthcare Holdings Employee Stock Ownership Plan10.33%
SBI SECURITIES CO., LTD.8.54%
Yamashita Hirotaka (山下 弘高)5.11%
Triple Four Investment Partnership4.97%
上田八木短資株式会社4.72%
Yamashita Koichi (山下 耕一)3.69%
株式会社十八親和銀行2.75%
2 other listed holders3.90%
Who owns it
HolderOwnership (%)
Yamashita Naoto (山下 尚登)24.44
Yamashita Healthcare Holdings Employee Stock Ownership Plan10.33
SBI SECURITIES CO., LTD.8.54
Yamashita Hirotaka (山下 弘高)5.11
Triple Four Investment Partnership4.97
上田八木短資株式会社4.72
Yamashita Koichi (山下 耕一)3.69
株式会社十八親和銀行2.75
2 other listed holders3.90
This company's documents
Timely disclosures
Threads